Patent Grant
9234190
The present invention relates to the field of genetic engineering, particularly to the field of recombinant protein production. The present invention provides a method for producing a hyperactive MuA transposase variant comprising at least one single-amino-acid-change, the method comprising the steps of modifying the nucleic acid encoding wild type MuA transposase so that the modified nucleic acid encodes a MuA transposase variant comprising at least one single-amino-acid change in its amino acid sequence, wherein said single-amino-acid change results in higher enzyme activity of the variant protein when compared to the wild type MuA transposase. The present invention also provides hyperactive MuA transposases and kits comprising the same.
Transposable genetic elements constitute a diverse group of discrete DNA segments with a capability of moving within and between genomes (1). They are abundant in all kingdoms of life and present in virtually every genome examined to date (1, 2). A wealth of data from sequenced genomes has implicated the fundamental importance of mobile DNA in shaping genomes during evolution (3-6). The increasing knowledge of DNA mobility mechanisms has facilitated the versatile use of transposable elements for research purposes and provided efficient tools for a variety of applications including genome-wide insertional mutagenesis, protein engineering, transgenesis, and gene therapy (7-9).
Phage Mu is a mobile DNA element encoding MuA transposase, the critical catalytic component of the mobilization machinery. MuA transposase belongs to the retroviral integrase superfamily of proteins. It catalyzes DNA cleavage and joining reactions via an initial assembly and subsequent structural transitions of a protein-DNA complex, known as the Mu transpososome, ultimately attaching transposon DNA into non-specific target DNA. The transpososome functions as a molecular DNA-modifying machine and has been used in a wide variety of molecular biology and genetics/genomics applications. It would be advantageous if the primary component of the Mu transpososome, the MuA transposase, could be modified for better performance with regard the applications. Here, we have mutated MuA protein using random mutagenesis methods in order to identify MuA variants with enhanced transpositional activity. Initially, we generated a pool of randomly mutated MuA-expressing plasmid clones, and by screening approx. 60.000 clones identified several hundred clones expressing hyperactive MuA variants. The identification employed a genetic screen using a quantitative in vivo transposition assay. This quantitative assay is based on the mobilization of a reporter transposon inside Escherichia coli cells. In this assay, individual transposition events are scored as blue microcolonies (papillae) growing on otherwise whitish bacterial colonies. The mutant-phenotype-causing nucleotide changes were then identified by DNA sequencing for 92 MuA-variant-expressing clones. Subsequently, the identified nucleotide changes, translated as amino acid changes, were mapped onto the primary amino acid sequence of MuA transposase. A total of 47 changes were selected for further scrutiny. Corresponding amino acid changes were introduced individually into MuA. These single-amino-acid-change MuA variants were then analyzed by the papillation analysis for their transpositional activity. This way, we identified 33 single-substitution MuA variants, which generated more than 2-fold excess papillae in the assay relative to the wild type MuA. We further showed that enhanced transpositional activities identified in the in vivo papillation assay were largely recapitulated in two other assays relevant for MuA-based transposon applications, namely: (i) introduction of transpososomes into bacterial cells for genomic integration and (ii) generation of recombinant molecules by in vitro transposition. These assays were performed using purified proteins expressed in Escherichia coli. In addition, we showed that by combining two or three activity-enhancing amino acid changes, cumulative enhancement in the protein activity could be attained. Thus, by combining several beneficial amino acid changes within a single MuA polypeptide, it is possible to generate MuA transposase variants that possess a substantially enhanced transpositional activity.
Many mobile DNA elements transpose via a DNA intermediate. This group of elements includes bacterial and eukaryotic transposons as well as transposing bacteriophages such as phage Mu. This phage utilizes DNA transposition as an important step in its propagation cycle. Owing to its efficient DNA mobilization capacity in vivo (10) and the early development of an in vitro system (11), phage Mu has served as an important model system for DNA transposition studies in general (12). Mu encodes MuA transposase, which catalyzes the critical steps of transposition: (i) initial cleavages at the transposon-host boundaries (donor cleavage) and (ii) covalent integration of the transposon into the target DNA (strand transfer). These steps proceed via sequential structural transitions within a nucleoprotein complex, a transpososome (12-16), the core of which contains four MuA molecules and two synapsed transposon ends (17,18). In vivo, the critical MuA-catalyzed reaction steps also involve the phage-encoded MuB targeting protein, host-encoded DNA architectural proteins (HU and IHF), certain DNA cofactors (MuA binding sites and transpositional enhancer sequence), as well as stringent DNA topology (19). The critical reaction steps mimicking Mu transposition into external target DNA can be reconstituted in vitro using MuA transposase, 50 bp Mu R-end DNA segments, and target DNA as the only macromolecular components (18, 20). Such a minimal system has been instrumental for the detailed analyses on the molecular mechanisms of Mu transposition (21-23). A versatile use of the reaction series with custom-designed substrates has generated a wealth of tools for molecular biology applications (24-29) and produced novel strategies for genetics/genomics research (30-34).
MuA is a 75-kDa protein (663 amino acids) and can be divided into structurally and functionally defined major domains (I, II, III) and subdomains (Iα, Iβ, Iγ; IIα, IIβ; IIIα, IIIβ) (35-39) (see also
Here, we have employed random mutagenesis to generate substitutions in MuA. From thousands of MuA substitution variants, we screened hyperactive transposase mutants and identified amino acid changes responsible for the observed phenotypic change. A combination of several hyperactivity-causing changes had a cumulative effect on the protein activity.
The term “transposon”, as used herein, refers to a nucleic acid segment, which is recognized by a transposase or an integrase enzyme and which is an essential component of a functional nucleic acid-protein complex (i.e. a transpososome) capable of transposition. Minimal nucleic acid-protein complex capable of transposition in the Mu transposition system comprises four MuA transposase protein molecules and a pair of Mu end sequences that are able to interact with MuA. The term “transposase” as used herein refers to an enzyme, which is an essential component of a functional nucleic acid-protein complex capable of transposition and which is mediating transposition. The term “transposase” also refers to integrases from retrotransposons or of retroviral origin.
The expression “transposition reaction” used herein refers to a reaction wherein a transposon inserts into a target nucleic acid. Essential components in a transposition reaction are a transposon and a transposase or an integrase enzyme. The method and materials of the present invention are exemplified by employing in vitro Mu transposition (18, 20).
The term “hyperactive” relates herein to enzyme hyperactivity, i.e. the activity of a modified enzyme variant is considerably higher than the activity of the wild type enzyme.
The term “wild type MuA transposase” relates herein to the amino acid sequence as set forth in SEQ ID NO:1 or enzymatically active deletion variants thereof.
The present invention is directed to a method for producing a hyperactive MuA transposase variant comprising at least one single-amino-acid-change, the method comprising the steps of modifying the nucleic acid encoding wild type MuA transposase so that the modified nucleic acid encodes a MuA transposase variant comprising at least one single-amino-acid change at the amino acid positions of SEQ ID NO:1 selected from the group consisting of: 59, 97, 160, 179, 233, 254, 258, 302, 335, 340, 345, 374, 447, 464, 478, 482, 483, 487, 495, 507, 539, 594, and 617; and wherein said single-amino-acid change results in higher enzyme activity of the variant protein when compared to the wild type MuA transposase.
Preferably, the method is directed to the production of a MuA transposase nucleic acid modified to encode at least one of the single-amino-acid-changes selected from the group consisting of: A59V, D97G, W160R, E179V, E233K, E233V, Q254R, E258G, G302D, I335T, G340S, W345C, W345R, M374V, F447S, F464Y, R478H, R478C, E482K, E483G, E483V, M4871, V495A, V507A, Q539H, Q539R, Q594R and 1617T.
As shown in
The present method may also comprise further step of expressing the modified nucleic acid in a host cell and preferably identifying those MuA variants the transposase activity of which is higher than the transposase activity of the wild type MuA. The identification step can be performed as a papillation assay disclosed below in the Experimental Section.
Another embodiment of the invention is a method for producing a hyperactive MuA transposase variant comprising at least two single-amino-acid-changes, the method comprising the steps of modifying the nucleic acid encoding wild type MuA transposase so that the modified nucleic acid encodes a MuA transposase variant comprising at least two single-amino-acid-changes at the amino acid positions of SEQ ID NO:1 selected from the group consisting of: 59, 97, 160, 179, 233, 254, 258, 302, 335, 340, 345, 374, 447, 464, 478, 482, 483, 487, 495, 507, 539, 594, and 617. Preferably, said MuA transposase variant produced comprises at least three single-amino-acid changes at the amino acid positions as described above. Advantageously, said two or three single-amino-acid-changes are in different domains of a MuA variant protein (see
In the present method, the nucleic acid encoding wild type MuA transposase is preferably modified by site-specific mutagenesis as described below in the Experimental Section. When the produced MuA variant comprises more than one single-amino-acid changes, the site-specific mutagenesis to produce the single-amino-acid changes may be done in one step or in a cumulative manner, wherein in the latter case the effect of each mutation to the cumulative activity of the variant is tested independently.
In one embodiment, the invention provides a hyperactive MuA transposase comprising at least one single-amino-acid-change at the amino acid positions of SEQ ID NO:1 selected from the group consisting of: 59, 97, 160, 179, 233, 254, 258, 302, 335, 340, 345, 374, 447, 464, 478, 482, 483, 487, 495, 507, 539, and 617, wherein said single-amino-acid change results in higher enzyme activity of the variant protein when compared to the wild type MuA transposase. For higher performance, the hyperactive MuA transposase may comprise two or three single-amino-acid-changes at said amino acid positions. Advantageously, said two or three single-amino-acid-changes are in different domains of a MuA variant protein (see
Preferably, the hyperactive MuA transposase comprises at least one (or preferably two or three) of the single-amino-acid-changes selected from the group consisting of: A59V, D97G, W160R, E179V, E233K, E233V, Q254R, E258G, G302D, I335T, G340S, W345C, W345R, M374V, F447S, F464Y, R478H, R478C, E482K, E483G, E483V, M4871, V495A, V507A, Q539H, Q539R, and 1617T.
In one preferred embodiment, the present invention provides a hyperactive MuA transposase comprising a single-amino-acid-change at position 233 of SEQ ID NO:1. More preferably, said hyperactive MuA transposase comprises or consists of the amino acid sequence as set forth in SEQ ID NO:2 with the single-amino-acid-change E233V. Another hyperactive MuA transposase disclosed by the present invention is the one comprising single-amino-acid-changes: W160R, E233K, and W345R, preferably comprising or consisting of the amino acid sequence as set forth in SEQ ID NO:3.
The present invention is further providing a kit for performing a transposase reaction, said kit comprising a hyperactive MuA transposase variant as defined above. Preferably, the kit comprises means for DNA sequencing. Said means can be selected from the group consisting of: buffers for performing transposition reaction, buffers for DNA sequencing, control DNA, transposase enzyme and DNA polymerase. The kit can be packaged in a suitable container and preferably it contains instructions for using the kit.
The publications and other materials used herein to illuminate the background of the invention, and in particular, to provide additional details with respect to its practice, are incorporated herein by reference. The present invention is further described in the following example, which is not intended to limit the scope of the invention.
Materials and Methods
Escherichia coli Strains and Culture Conditions
DH10B (54) was used as a standard cloning host and DH5α (Invitrogen) for routine plasmid DNA isolation as well as for the papillation analysis. MuA transposase variants were expressed in BL21(DE3)(pLysS) (Novagen). MC1061 (55) was used as a recipient strain to score in vitro transposition reaction products. For standard use, bacteria were grown in Luria-Bertani (LB) medium as described (63) supplemented with ampicillin (Ap) and chloramphenicol (Cm) when required. Electrocompetent and standard competent cells were prepared as described by (56, 57), respectively.
Enzymes, Reagents, DNA Techniques and Plasmids.
Commercial proteins and reagents are listed in Table 1. MuAE392Q was purified as described (17). Oligonucleotides are listed in Table 2. Plasmid DNA was isolated using appropriate QIAGEN kits. Plasmids are described in Table 3. Standard DNA techniques were performed as described (56). Transposon Cat-Mu has been described (20). It was isolated from its carrier plasmid by BglII digestion and purified by anion exchange chromatography as described (20). DNA sequence determination was performed at the DNA sequencing facility of the Institute of Biotechnology (University of Helsinki) by using the BigDye terminator cycle sequencing kit and ABI 377 XL sequencer, both from Applied Biosystems.
Generation of MuA Mutant Libraries.
To construct MuA mutant libraries, error-prone PCR was performed using two different enzyme preparations: Taq DNA polymerase from Promega and Mutazyme II DNA polymerase mixture from Stratagene.
Taq DNA polymerase mutagenesis was performed essentially as described (65). Each standard PCR reaction (50 μl) contained 50 ng (12 fmol) plasmid pTLH2 (53) as a template, 0.3 μM each of the primers HSP492 and HSP493, 200 μM each dNTPs and 5 U Taq DNA polymerase in Taq DNA polymerase reaction buffer (10 mM Tris-HCl (pH 9.0 at 25° C.), 50 mM KCl, 1.5 mM MgCl2, 0.1% (v/v) Triton X-100). Three independent amplifications were performed in which 0, 1, or 2 μl of mutagenic buffer (4 mM dTTP, 4 mM dCTP, 27.5 mM MgCl2, and 2.5 mM MnCl2) was included in the standard 50 μl reaction. PCR amplification employed initial 2 min at 94° C., 25 cycles of amplification (1 min at 94° C., 1 min at 59° C., 2.5 min at 72° C.), and final 10 min at 72° C. PCR products were purified using QIAquick PCR purification kit, digested with NcoI and EcoRI, and subjected to preparative electrophoresis on a 1.0% SeaPlaque GTG agarose in TAE buffer (56). The 2-kb MuA-encoding DNA segment (Gene Bank P07636), was isolated by QIAquick MinElute Gel Extraction Kit and ligated into the plasmid pTLH1 (51) digested with NcoI and EcoRI. Aliquots of the ligation mixtures were electroporated into DH10B cells. MuA variants containing plasmid clones were selected on LB-Ap-Cm plates (100 μg/ml Ap, 10 μg/ml Cm). From each ligation mixtures, approximately 6×104 colonies were pooled and, for plasmid preparation, grown in LB-Ap-Cm medium (100 μg/ml Ap, 10 μg/ml Cm) at 37° C. for 2 h.
Mutazyme II DNA polymerase mutagenesis was performed essentially as described (53) with pALH6 (53) as a template and HSP519/HSP492 as a primer pair for PCR amplification. Two independent mutant libraries were constructed with Mutazyme II DNA polymerase using five and ten amplification cycles. PCR products were extracted from a preparative agarose gel as described above and further amplified using Vent DNA polymerase in non-mutagenic reaction conditions as follows. Each amplification reaction (50 μl) contained approximately 10 ng of gel-purified PCR product as template, 0.5 μM each of the primers HSP492 and HSP493, 200 μM each dNTPs and 1 U Vent DNA polymerase (in ThermoPol reaction buffer: 20 mM Tris-HCl (pH 8.8 at 25° C.), 10 mM KCl, 10 mM (NH4)2SO4, 4 mM MgSO4, 0.1% (v/v) Triton X-100). PCR employed initial 5 min at 95° C., 25 cycles of amplification (45 s at 95° C., 1 min at 59° C., 2.5 min at 72° C.), and final 5 min at 72° C. PCR products were purified, digested, gel-isolated, cloned into pTLH1, and electroporated into DH10B cells as described above. Approximately 6×104 colonies were pooled and grown for DNA isolation as above.
Papillation Assay.
MuA mutant variants were assayed for their transpositional activity using an in vivo analysis that is based on transposon mobilization (51). This quantitative assay scores transposition events as blue microcolonies (papillae) growing on otherwise whitish E. coli colonies. It takes advantage of a plasmid, which contains a lacZ-containing reporter transposon and a cassette for arabinose-inducible MuA expression. Briefly, mutant plasmids were transformed into standard competent DH5α cells (50 μl), and the cells were plated onto LB agar plates supplemented with 100 μg/ml Ap, 20 μg/ml Cm, 0.05% lactose, 40 μg/ml Xgal, and 1×10−4 1% arabinose. The plates were normally incubated at 30° C. for 115 h.
To quantify highly hyperactive protein activities, plates were incubated at 25° C. for 140 h. For each data point, three representative colonies (diameter ˜5 mm) were photographed using an Olympus (Tokyo, Japan) ColorView II digital camera attached to an Olympus SZX12 stereomicroscope equipped with Zeiss (Oberkochen, Germany) KL1500 LCD cold light source. The number of papillae in each colony was enumerated manually by the use of AnalySIS software (Soft Imaging System, Olympus).
Construction of Plasmids Encoding a MuA with Site-Specific Mutation.
Site-specific mutagenesis for each MuA variant was performed by PCR using a primer pair with one mutagenic primer and one non-mutagenic primer (Table 2). Each amplification reaction (50 μl) contained 100 ng pTLH4 as template, 0.5 μM each primer, 200 μM each dNTPs and 1U Phusion DNA polymerase (in Phusion HF buffer). An initial denaturation step (2 min at 98° C.) was followed by 10 cycles of amplification (30 s at 98° C., 1 min gradient 50-66° C., 7 min at 72° C.), and final 5 min at 72° C. Each amplified product was isolated from 0.5% SeaPlaque GTG agarose gel and purified using MinElute Gel exraction kit. Each product was treated with T4 polynucleotide kinase and circulated by ligation. The ligation products were transformed into E. coli, and each mutant plasmid was isolated. Mutant MuA variants were cloned into papillation vector pTLH1 cleaved with NcoI and KpnI. Sequences of MuA variants were confirmed by sequencing.
Production and Purification of Transposase Proteins.
The MuA variants were cloned into expression vector pET3d. Each respective protein variant was overexpressed and purified by the following modification of the described procedure (17). BL21(DE3)(pLysS) cells containing a MuA expression plasmid were grown in LB media (120 ml) containing antibiotics (100 μg/ml Ap and 35 μg/ml Cm) at 37° C. to an OD600 of less than 1. Cells were then collected by centrifugation and shifted into LB medium (1.2 liters) supplemented with Ap (100 μg/ml). Cell propagation was continued at 28° C. to an OD600 of 0.4-0.5. Protein expression was induced by the addition of IPTG (0.4 mM). Cells were harvested 2 h post-induction by centrifugation at 4° C., resuspended in an equal weight of 50 mM Tris-HCl, pH 8.0, 10% sucrose, 1 mM DTT, frozen in liquid nitrogen, and stored at −80° C. until used for protein purification.
Cell lysis and ammonium sulfate precipitation was performed as described (17), except that the precipitated MuA protein pellet was resuspended in HEDG plus 500 mM KCl (HEDG is 25 mM HEPES, pH 7.6, 0.1 mM EDTA, 1 mM DTT, 10% glycerol) to reach the original volume before precipitation. The protein solution was purified using phosphocellulose and hydroxylapatite columns as described (17) with the following modifications of the procedure. The protein solution was loaded onto 1.4 ml phosphocellulose (P11; Whatman) filled poly-prep column (Bio-Rad). The column was developed with a 7.4 vol gradient from 0.3-1.5 M KCl. Protein concentration of fractions was determined with the Bio-Rad Protein Assay using microtiter plate protocol based on the Bradford dye-binding procedure (58). The peak fractions were pooled and adjusted to conductivity of 10 mM KPO4 and 500 mM KCl by addition HDG (HDG is 25 mM HEPES, pH 7.6, 1 mM DTT, 10% glycerol). The fraction was loaded onto a 0.45 ml hydroxyapatite (Macro-Prep Ceramic Hydroxyapatite Type I, Bio-Rad) packed in HR 5/2 (GE Healthcare Life Sciences) column in ÄKTApurifier system. The column was equilibrated in HDG plus 10 mM KPO4 and 500 mM KCl. The column was developed with a 10 vol gradient from 10 mM-1M potassium phosphate in HDG plus 500 mM KCl. Peak fractions were pooled and dialyzed against HEDG plus 300 mM NaCl. Pooled fractions were frozen in liquid nitrogen and store at −80° C. Purity of protein preparations were confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and nuclease assay. Protein concentration was determined spectrocopically using the following extinction coefficient ε1 mg/ml=1.58.
Transpososomes.
Transpososomes were assembled as previously described (32). The assembly reaction (40 μl) contained 55 nM transposon DNA fragment, 245 nM MuA, 150 mN Tris-HCl pH 6.0%, 50% (v/v) glycerol, 0.025% (w/v) Triton X-100, 150 mM NaCl, and 0.1 mM EDTA. The reaction was carried out at 30° C. for 2 h. Transpososome preparations were frozen in liquid nitrogen and stored at −80° C. The formation of stable protein-DNA complexes with various transposase mutants were analysed by agarose/BSA/heparin gels as described (32).
In Vivo Chromosomal Integration of Mini-Mu Transposon.
Genomic integration activity into Escherichia coli chromosome was determined by the following modification of the described procedure (32). The transpososome assembly reaction mixture was diluted 1:8 with water and individual aliquots of 1 μl were electroporated into electrocompetent MC1061 cells (25 μl).
In Vitro Transposition Reactions and Biological Selection of Integrants.
Transposition activity was determined by in vitro transposition reaction (24). Standard reactions (25 μl) contained 0.5 pmol transposon DNA, 500 ng (0.4 pmol) pUC19 target DNA, 2.7 pmol (0.22 μg) MuA variant, 25 mM Tric-HCl, pH 8.0, 100 μg/ml BSA, 15% (w/v) glycerol, 0.05% (w/v) Triton X-100, 126 mM and 10 mM MgCl2. Reactions were carried out for 1 h at 30° C. and stopped by freezing in liquid nitrogen. Following addition of 0.3 vol loading dye (0.1% bromophenol blue, 2.5% SDS, 50 mM EDTA, 25% Ficoll 400), transposition reaction products were analyzed by electrophoresis on a 0.8% SeaKem LE agarose gel in 1×TAE buffer (56). For biological selection of integrants, 5 μl of the transposition reaction products was transformed into competent E. coli cells (56).
Results
The Mu transposition system can be exploited in many types of molecular biology and genetic/genomics applications (20, 24-31), including gene delivery into the genomes of gram-negative and gram-positive bacteria as well as those of yeast and mammalian cells (32-34). In each application, the efficiency of transposon integration into target DNA is critical, and therefore it would be beneficial if more efficient insertion reaction could be reconstituted. Previous studies with other transposons have indicated that it is possible to generate enhanced transpositional activities by mutating the critical component of the integration apparatus, the transposase (59-62). In this study we set out to search for hyperactive MuA variants. For that we employed two random mutagenesis methods both described in detail by Rasila et al. (2009) (53, see also
We screened approx. 60.000 individual MuA mutant variants, and from these variants identified 92 clones with an increased transpositional activity. These clones were subjected to sequence analysis to identify nucleotide changes. The changes were evaluated in translation and those generating an amino acid change were mapped onto the MuA primary amino acid sequence. This procedure generated a map of mutations potentially implicated in enhanced transpositional activity. Of these amino acid changes, a total of 47 changes were individually introduced in MuA. These substitution mutants were then analyzed for their transpositional activity using the papillatioin assay (
We next purified 30 MuA variants to study them in applicationally relevant assays. First, we assayed their proficiency in promoting gene delivery into bacterial genome. As shown in
Subsequently, we engineered two or three critical mutations into MuA (
aTransposition frequencies were measured in papillation assay at 25° C. for 140 h on standard papillation medium (LB, Ap 100 μg/ml, Cm 20 μg/ml, Xgal 40 μg/ml, lactose 0.05%, arabinose 1 × 10−4%). The number of papillae was enumerated. Papillae number for the wild type MuA protein was 0 ± 0 under these assay conditions. As indicated in FIG. 5, mutations A234V and T543A do not enhance papillation.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20125586 | May 2012 | FI | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/FI2013/050586 | 5/30/2013 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2014/013127 | 1/23/2014 | WO | A |
| Entry |
|---|
| Database Genbank [online] Mar. 15, 2005, Accession No. EHX94064, transposase [Escherichia coli DEC14D] [retrieved on Mar. 15, 2013]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.gov/protein/EXH94064> & sequence alingment with SEQ ID No. 1. |
| Database Uniprot [online] Oct. 19, 2011, Accession No. G0FCG6, transposase [retrieved on Mar. 15, 2013]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/G0FCG6> & sequence alingment with SEQ ID No. 1. |
| Epicentre Hyper Mu MuA transposase [online brochure], Epicentre Biotechnologies (2005), [last modified Feb. 5, 2005] [retrieved on Mar. 18, 2013]. Retrieved from the Internet: <URL www.biomarket.cc/UpFiles/product/THM03210.pdf>. |
| International Search Report issued Sep. 9, 2013, in PCT International Application No. PCT/FI2013/050586. |
| Kim et al., “N-Terminal Domain-Deleted Mu Transposase Exhibits Increased Transposition Activity with Low Target Site Preference in Modified Buffers,” J. Mol. Microbiol. Biotechnol. (2009), vol. 17, pp. 30-40. |
| Naigamwalla et al., “Mutations in domain IIIα of the Mu Transposase: Evidence Suggesting an Active Site Component which Interacts with the Mu-Host Junction,” J. Mol. Biol. (1998), vol. 282, pp. 265-274. |
| Pajunen et al., “Universal platform for quantitative analysis of DNA transposition,” Mobile DNA (2010), vol. 1, No. 24, pp. 1-14. |
| Rasila et al., “Flexibility in MuA Transposase Family Protein Structures: Functional Mapping with Scanning Mutagenesis and Sequence Alingment of Protein Homologues,” PLoS ONE (May 2012), vol. 7, No. 5, e37922, pp. 1-20. |
| Rasila, T., Functional Mapping of Mu Transposition Machinery: MuA Protein Modification and Engineering for Hyperactivity, Doctoral disseration, 2013, University of Helsinki, Faculty of Biological and Environmental Sciences, Department of Biosciences, Division of Biochemistry and Biotechnology, ISBN: 978-952-10-8718-9. |
| Search Report issued Mar. 20, 2013, in Finnish Patent Application No. 20125586. |
| Number | Date | Country | |
|---|---|---|---|
| 20150147753 A1 | May 2015 | US |
